摘要
Abstract
Objective To investigate the effects of modified Guizhi Fuling Pills combined with danazol on the myoma volume and the sex hormone levels in patients with uterine myoma(UM).Methods A total of 97 UM patients were selected as the study subjects and were divided into a control group(n=48)or an observation group(n=49)by the random number table method.The control group was treated with danazol,based on which the observation group was treated with modified Guizhi Fuling Pills additionally,and both groups were treated for 3 menstrual cycles.The clinical efficacy;myoma volume and serum levels of sex hormones,transforming growth factor(TGF)-β1,vascular endothelial growth factor(VEGF),and matrix metalloproteinase(MMP)-9 before and after treatment;and adverse reactions during treatment were compared between the two groups.Results After being treated for 3 menstrual cycles,the total effective rate of the observation group(93.88%)was higher than that of the control group(79.17%)(P<0.05);the myoma volumes in both groups were smaller than those before treatment,and the myoma volume was smaller in the observation group than in the control group's(all P<0.05);the serum levels of follicle-stimulating hormone,estradiol,luteinizing hormone,TGF-β1,VEGF,and MMP-9 in the two groups were lower than those before treatment,and the levels of the abovementioned indicators in the observation group were lower than those in the control group(all P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Modified Guizhi Fuling Pills combined with danazol has a definite effect in the treatment of UM,which can shrink the myoma volume,regulate the secretion of sex hormones,and lower the serum levels of TGF-β1,VEGF,and MMP-9,with good safety.关键词
子宫肌瘤/加味桂枝茯苓丸/达那唑/性激素/肌瘤体积/转化生长因子/血管内皮生长因子/基质金属蛋白酶Key words
Uterine myoma/Modified Guizhi Fuling Pills/Danazol/Sex hormone/Myoma volume/Transforming growth factor/Vascular endothelial growth factor/Matrix metalloproteinase分类
医药卫生
